Table 1.
Baseline characteristics, by treatment group (N = 216)
| Variables | DOT | SAT |
|---|---|---|
| Number of patients | n = 109 | n = 107 |
| Female; N (%) | 45 (41) | 41 (38) |
| Age group; N (%) | ||
| 3-7 years | 34 (31) | 20 (19) |
| 8-13 years | 26 (24) | 13 (12) |
| ≥ 14 years | 49 (45) | 74 (69) |
| G6PD mutation status; N (%) | ||
| Wild-type | 81 (75) | 84 (81) |
| G6PD Mahidol: Homozygous | 2 (2) | 2 (2) |
| G6PD Mahidol: Hemizygous | 9 (8) | 11 (10) |
| G6PD Mahidol: Heterozygous | 16 (15) | 7 (7) |
| Body temperature at Day 0 (°C); Mean ± SD | 37.8 ± 1.2 | 37.8 ± 1.2 |
| Duration of fever pre-treatment; N (%) | ||
| 0-2 days | 62 (57) | 50 (47) |
| 3+ days | 46 (43) | 57 (53) |
| Parasite count at Day 0 (/µl); Geometric mean (range) | 1,890 (32-75600) | 2,533 (32-400000) |
| Gametocyte presence at Day 0; N (%) | 45 (41) | 37 (35) |
| Gametocyte count at Day 0 (/µl); Geometric mean (range) | 141 (16-1600) | 141 (16-8160) |
| P. vivax genotype (pvcs gene) infected at Day 0; N (%) | ||
| VK210 | 95 (91) | 84 (80) |
| VK247 | 4 (4) | 12 (11) |
| VK210&VK247 | 5 (5) | 9 (9) |
| Number of P. vivax genotype infections; N (%) | ||
| Single | 85 (82) | 84 (80) |
| Multiple infection | 19 (18) | 21 (20) |